New drug shows promise for Long-Term control of chronic hives

NCT ID NCT06736262

Terminated Disease control Sponsor: Jasper Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study is testing the long-term safety and effectiveness of a drug called briquilimab for people with chronic hives. It includes 67 participants who have already completed a previous trial with the same drug. The goal is to see if briquilimab remains safe and helps control hives over a longer period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: briquilimab
What this could lead to: If successful, this could point toward a new long-term treatment option for chronic hives, reducing symptoms and improving quality of life.
What could go wrong: This is an early-phase extension study with only 67 participants, so results may not apply to everyone. Long-term safety and effectiveness are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria chronic urticaria cold urticaria familial dermatographia Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URTICARIA CHRONIC

Contacts and locations

Locations

Investigative Site 101

Baltimore, Maryland, 21224, United States
Investigative Site 103

Cincinnati, Ohio, 45236, United States
Investigative Site 105

San Diego, California, 92123, United States
Investigative Site 108

Little Rock, Arkansas, 72205, United States
Investigative Site 109

Boise, Idaho, 83706, United States
Investigative Site 110

Indianapolis, Indiana, 46250, United States
Investigative Site 111

Murray, Utah, 84107, United States
Investigative Site 115

Seattle, Washington, 98101, United States
Investigative Site 116

Tampa, Florida, 33613, United States
Investigative Site 118

Birmingham, Alabama, 35244, United States
Investigative Site 121

White Marsh, Maryland, 21162, United States
Investigative Site 123

Lafayette, Louisiana, 70508, United States
Investigative Site 124

Normal, Illinois, 61761, United States
Investigative Site 201

Berlin, 12203, Germany
Investigative Site 202

Marburg, Hesse, 35043, Germany
Investigative Site 204

Münster, North Rhine-Westphalia, 48149, Germany
Investigative Site 206

Lübeck, Schleswig-Holstein, 23538, Germany
Investigative Site 209

Dresden, Saxony, 01307, Germany
Investigative Site 210

München, Bavaria, 80802, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.